about
Interferon Beta for Primary Progressive Multiple SclerosisComprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseasesRegional white matter atrophy--based classification of multiple sclerosis in cross-sectional and longitudinal dataAntigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosisEvaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic ReviewBrain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosisNew and emerging immune-targeted drugs for the treatment of multiple sclerosisFingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapyA Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future PerspectivesDisease course heterogeneity and OCT in multiple sclerosisPrimary progressive multiple sclerosis: current therapeutic strategies and future perspectivesGrey matter damage in multiple sclerosis: a pathology perspectiveClinical, MRI, and CSF markers of disability progression in multiple sclerosis.Intracranial delivery of interleukin-17A via adeno-associated virus fails to induce physical and learning disabilities and neuroinflammation in mice but improves glucose metabolism through AKT signaling pathwaySynchronization and variability imbalance underlie cognitive impairment in primary-progressive multiple sclerosis.Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis.An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosisRetinal nerve fiber layer thickness in subgroups of multiple sclerosis, measured by optical coherence tomography and scanning laser polarimetry.Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort.Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.Understanding unexpected courses of multiple sclerosis among patients using complementary and alternative medicine: A travel from recipient to explorer.The role of advanced magnetic resonance imaging techniques in primary progressive MS.Genetic association of multiple sclerosis with the marker rs391745 near the endogenous retroviral locus HERV-Fc1: analysis of disease subtypesThe role of infections in the pathogenesis and course of multiple sclerosis.Myelin water imaging reflects clinical variability in multiple sclerosisCorrelation of diffusion and metabolic alterations in different clinical forms of multiple sclerosis.Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis.Comparative gene expression analysis in mouse models for multiple sclerosis, Alzheimer's disease and stroke for identifying commonly regulated and disease-specific gene changesNew approaches in the management of multiple sclerosis.Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration.FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.Increasing Incidence in Relapsing-Remitting MS and High Rates among Young Women in Finland: A Thirty-Year Follow-Up.Can meditation influence quality of life, depression, and disease outcome in multiple sclerosis? Findings from a large international web-based studyOpposite roles of NMDA receptors in relapsing and primary progressive multiple sclerosisA PARK2 polymorphism associated with delayed neuropsychological sequelae after carbon monoxide poisoningDiffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types.Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.
P2860
Q24240620-D1D4D5DE-AE4E-4438-9F27-9FBDE8041B93Q24273331-389532C1-6044-458E-A4BA-A4F4841D9A31Q24647968-9A633CED-7BEB-4B2E-BD48-6A471FEE20D3Q24650147-1B3C230E-4731-4ADE-B0A1-B57817720B2EQ26782408-0D8FCEFC-7D63-41A4-829B-978118ED7EABQ26799233-346F9381-1E47-4B49-9CA3-2DAAB2D13AEDQ26827402-B007B5EF-8D70-4C57-A9CF-F99E5A0B46D9Q26997067-853E11A0-6093-4917-BC63-FFF85D2BA70DQ27011473-B65B59D2-E9E6-44AE-B74D-BF3AF5530DFCQ28068709-92105505-059D-40F6-AAE4-5BD122A9820FQ28305473-027CC906-FF76-4566-9382-277DC9FB72FDQ29030703-95371A99-4537-4BA1-A864-88F609F37A72Q30586246-67A60F2F-51D7-4B2F-9CC3-DE93EC01F057Q30712257-B2781783-E02E-43E8-B86D-4B9BF6B0A29CQ30724821-5E605A62-A491-4871-9B3E-111B8FD57AF7Q30846662-5B60E81A-B44C-4C08-85C0-86536BB7C1B4Q30988577-F3ECE333-5E19-411B-BBB9-5929A1F522F6Q31002774-B3FAD919-93E3-41BC-A4F0-DB0FF3C1EED0Q33576003-C36D9D2C-6FD2-40A4-B105-A11F7240E409Q33712460-CF39C96B-88ED-408E-B009-8679334BA03AQ33810559-816B93C2-1320-43F7-BDBA-72692F4F36E2Q33975288-BE546FF4-B225-4820-AD69-0E27CEF0EDBDQ33981654-C6C2D567-22AB-4199-9E77-8A53E6B504E2Q34062426-BFD5256A-556E-470F-9638-E150A0733F38Q34075874-0276500A-B2EE-4432-91A6-1ACDEE501F9EQ34095719-C0772A0F-B073-4FB1-AF97-8B7D093AFC5FQ34221185-2B18992B-EF6E-48FA-AC3A-1D3F0DBE4632Q34241223-7EEA6617-D20E-4D4B-B1CD-763194998F3BQ34344447-F5A5D784-3261-48B3-8B4F-2A718425D1FBQ34381637-0637D6B9-B29C-4BD1-AABD-4DD28A2D77D9Q34389528-C2C40A1D-3E3F-4AA2-80E6-0887A5C34A71Q34423587-B74ECD55-F5A0-4949-949B-64086881C1E9Q34463760-9453C5C6-ED91-4F27-9B75-F3479025E109Q34490581-DA87583A-A5A6-4DF0-972E-D0C7E308EFCBQ34561939-C0BD6EDA-C6F1-4B8B-B98E-1BA6C2C05FEDQ34575351-3FEE0194-59DB-44C5-8498-F9F5864FC162Q34807095-0B4051D5-517B-4940-8D43-80B003A9B0AAQ34996429-2C5586EF-37EC-406D-8686-C71B32D6A80BQ35009150-3223E8E4-5DF1-42DB-ABD7-DC9988883CA4Q35295564-96E61825-043D-48A8-8F99-7A01776FAB78
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Primary-progressive multiple sclerosis.
@ast
Primary-progressive multiple sclerosis.
@en
type
label
Primary-progressive multiple sclerosis.
@ast
Primary-progressive multiple sclerosis.
@en
prefLabel
Primary-progressive multiple sclerosis.
@ast
Primary-progressive multiple sclerosis.
@en
P1433
P1476
Primary-progressive multiple sclerosis.
@en
P2093
David H Miller
Siobhan M Leary
P304
P356
10.1016/S1474-4422(07)70243-0
P577
2007-10-01T00:00:00Z